EMD-RX5 demonstrates excellent safety and bioavailability

○ higher CBD exposures 3 to 8 hours after dosing, indicating EMD-RX5 provides more predictable drug exposure over time; suited for non-acute indications and supporting a preferred once to twice daily dosing regime ○ twice the bioavailability compared to other, plant-derived CBD products with published pharmacokinetics data (see Figure 1) ● EMD-RX5 Phase 1 results expand Emyria’s program to registe